The Breathlessness, Cough, and Sputum Scale: The Development of Empirically Based Guidelines for Interpretation

Chest

Volumn 124, Issue 6, 2003, Pages 2182-2191

  Leidy, Nancy Kline ^a   Rennard, Stephen I ^b   Schmier, Jordana ^a   Jones, M Kathryn C ^c   Goldman, Mitch ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Bronchitis; Clinical trials; COPD; Cough; Dyspnea; Emphysema; Exacerbation; Health related quality of life; Instrument; Patient reported outcome; Sputum; St. George Respiratory Questionnaire; Symptoms

Indexed keywords

DOPAMINE 2 RECEPTOR STIMULATING AGENT; SIBENADET; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREATHLESSNESS COUGH AND SPUTUM SCALE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SAINT GEORGE RESPIRATORY QUESTIONNAIRE SCORE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYMPTOM; SYMPTOMATOLOGY;

EID: 0347624393     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.6.2182     Document Type: Article

References (26)

1. National Heart, Lung, and Blood Institute. Global Initiative for Chronic Obstructive Lung Disease. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, 2001. Publication No. 2701A. Available from: http://www.goldcopd.com/workshop/ index.html; accessed November 10, 2003
2. Siafakas NM, Vermeire P, Price NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): The European Respiratory Society Task Force. Eur Respir J 1995; 8:1398-1420
3. American Thoracic Society Board of Directors. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S120
4. COPD Guideline Group of the Standards of Care Committee of the British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52(suppl 5):S1-S28
5. Mahler DA, Faryniarz K, Tomlinson D, et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest 1992; 102:395-401
6. Eltayara L, Becklace MR, Volta CA, et al. Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154(6 pt 1):1726-1734
7. McGavin CR, Artvinli M, Naoe H, et al. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. BMJ 1978; 2:241-243
8. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377-381
9. Selim AJ, Ren XS, Fincke G, et al. A symptom-based measure for the severity of chronic lung disease: results from the Veterans Health Study. Chest 1997; 111:1607-1614
10. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327
11. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42:773-778
12. Leidy NK, Schmier J, Jones MKC, et al. Evaluating symptoms in COPD: Validation of the Breathlessness, Cough and Sputum Scale. Respir Med 2003; 97(Suppl A):S59-S70
13. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York, NY: McGraw-Hill, 1994
14. Celli B, Halpin D, Hepburn R, et al. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). Respir Med 2003; 97(Suppl A):S35-S43
15. 2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of COPD: results of a large-scale clinical investigation. Respir Med 2002; 97(Suppl A):S23-S33
16. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283-1289
17. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale NJ: Lawrence Erlbaum Associates, 1988
18. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1618-1623
19. Seemungal T, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-1422
20. Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1608-1613
21. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217-224
22. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium: Dutch/Belgian Tiotropium Study-Group. Eur Respir J 2002; 19:209-216
23. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74-81
24. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease: International COPD Study Group. Lancet 1998; 351:773-780
25. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303
26. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117(Suppl 2):398S-401S